Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer

Authors

Dong Liang (ORCID: https://orcid.org/0000-0001-6632-8066)
Hareesh B. Nair
Megharani Mahajan (ORCID: https://orcid.org/0000-0002-6259-5754)
Huan Xie (ORCID: https://orcid.org/0000-0002-0591-5619)
John R. Sanchez (ORCID: https://orcid.org/0000-0002-5362-1025)
Jessica D. Johnson (ORCID: https://orcid.org/0000-0002-5331-7461)
Sridharan Jayamohan (ORCID: https://orcid.org/0000-0002-8430-0881)
Yang Wang (ORCID: https://orcid.org/0000-0002-0429-9412)
Suryavathi Viswanadhapalli
Manjeet K. Rao (ORCID: https://orcid.org/0000-0001-7573-2677)
Gangadhara R. Sareddy (ORCID: https://orcid.org/0000-0001-9977-3932)
Panneerdoss Subbarayalu (ORCID: https://orcid.org/0000-0002-9028-7193)
K.V. Dileep (ORCID: https://orcid.org/0000-0002-7456-4226)
Ratna K. Vadlamudi (ORCID: https://orcid.org/0000-0003-2849-4076)
Alondra L. Rodriguez Sanchez

Publication Details

Published: 2025-09-02
DOI: https://doi.org/10.1158/1535-7163.30028867
Primary Topic: Glycosylation and Glycoproteins Research
Type: article
Field-Weighted Citation Impact: 0.00

Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer

Dong Liang, Hareesh B. Nair, Megharani Mahajan, Huan Xie, John R. Sanchez, Jessica D. Johnson, Sridharan Jayamohan, Yang Wang, Suryavathi Viswanadhapalli, Manjeet K. Rao, Gangadhara R. Sareddy, Panneerdoss Subbarayalu, K.V. Dileep, Ratna K. Vadlamudi, Alondra L. Rodriguez Sanchez

September 2, 2025article en

Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer

Authors

Publication Details

Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer

Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.